This systematic review highlights the distinct profiles of SGLT2 inhibitors, DPP-4 inhibitors, metformin, and insulin in the management of T2DM, offering valuable insights into their comparative efficacy and long-term outcomes. This evidence concerns the gene INS and type 2 diabetes mellitus.